Publication:
Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.

dc.contributor.authorBover, Jordi
dc.contributor.authorUreña-Torres, Pablo
dc.contributor.authorGórriz, José Luis
dc.contributor.authorLloret, María Jesús
dc.contributor.authorda Silva, Iara
dc.contributor.authorRuiz-García, César
dc.contributor.authorChang, Pamela
dc.contributor.authorRodríguez, Mariano
dc.contributor.authorBallarín, José
dc.date.accessioned2023-01-25T08:36:11Z
dc.date.available2023-01-25T08:36:11Z
dc.date.issued2016-08-30
dc.description.abstractCardiovascular (CV) calcification is a highly prevalent condition at all stages of chronic kidney disease (CKD) and is directly associated with increased CV and global morbidity and mortality. In the first part of this review, we have shown that CV calcifications represent an important part of the CKD-MBD complex and are a superior predictor of clinical outcomes in our patients. However, it is also necessary to demonstrate that CV calcification is a modifiable risk factor including the possibility of decreasing (or at least not aggravating) its progression with iatrogenic manoeuvres. Although, strictly speaking, only circumstantial evidence is available, it is known that certain drugs may modify the progression of CV calcifications, even though a direct causal link with improved survival has not been demonstrated. For example, non-calcium-based phosphate binders demonstrated the ability to attenuate the progression of CV calcification compared with the liberal use of calcium-based phosphate binders in several randomised clinical trials. Moreover, although only in experimental conditions, selective activators of the vitamin D receptor seem to have a wider therapeutic margin against CV calcification. Finally, calcimimetics seem to attenuate the progression of CV calcification in dialysis patients. While new therapeutic strategies are being developed (i.e. vitamin K, SNF472, etc.), we suggest that the evaluation of CV calcifications could be a diagnostic tool used by nephrologists to personalise their therapeutic decisions.
dc.identifier.doi10.1016/j.nefro.2016.05.023
dc.identifier.essn1989-2284
dc.identifier.pmid27595517
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.nefro.2016.05.023
dc.identifier.urihttp://hdl.handle.net/10668/10414
dc.issue.number6
dc.journal.titleNefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
dc.journal.titleabbreviationNefrologia
dc.language.isoen
dc.language.isoes
dc.organizationIMIBIC
dc.page.number597-608
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCalcificación vascular
dc.subjectCalcifilaxis
dc.subjectCalcimimetics
dc.subjectCalcimiméticos
dc.subjectCalciphylaxis
dc.subjectChronic kidney disease
dc.subjectChronic kidney disease-mineral and bone disorders
dc.subjectEnfermedad renal crónica
dc.subjectFosfato
dc.subjectPhosphate
dc.subjectVascular calcification
dc.subjectVitamin D
dc.subjectVitamina D
dc.subject.meshCalcimimetic Agents
dc.subject.meshChronic Disease
dc.subject.meshChronic Kidney Disease-Mineral and Bone Disorder
dc.subject.meshDisease Progression
dc.subject.meshHumans
dc.subject.meshRenal Dialysis
dc.subject.meshRenal Insufficiency, Chronic
dc.subject.meshVascular Calcification
dc.titleCardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.
dc.title.alternativeCalcificaciones cardiovasculares en la enfermedad renal crónica: Potenciales implicaciones terapéuticas.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number36
dspace.entity.typePublication
Files